カテゴリー： 世界, 医療/バイオ, Market Research Future

世界のポンペ病治療市場（〜2030年）

【英語タイトル】Global Pompe Disease Treatment Market Research Report Forecast to 2030

Market Research Futureが出版した調査資料（MRF23JUN012）・商品コード：MRF23JUN012
・発行会社（調査会社）：Market Research Future
・発行日：2023年4月
・ページ数：123
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール
・調査対象地域：グローバル
・産業分野：医療
◆販売価格オプション（消費税別）
Single User（印刷不可、Online Access）USD4,950 ⇒換算￥752,400見積依頼/購入/質問フォーム
Enterprisewide Price（印刷可）USD7,250 ⇒換算￥1,102,000見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
❖ レポートの概要 ❖

Market Research Future社の本調査レポートは、ポンペ病治療の世界市場について総合的に分析し、今後の市場動向を予測した資料です。本書は、エグゼクティブサマリー、イントロダクション、調査手法、市場動向、市場要因分析、種類別（遅発性ポンペ病、従来型乳児ポンペ病、非従来型乳児ポンペ病）分析、治療別（酵素補充療法（ERT）、遺伝子治療、その他）分析、エンドユーザー別（病院・診療所、研究・学術機関）分析、地域別（南北アメリカ、ヨーロッパ、アジア太平洋、中東・アフリカ）分析、競争状況、企業情報などの項目を掲載しています。なお、主要企業として、Oxyrane（UK）、Valerion Therapeutics（US）、AVROBIO, Inc.（US）、Audentes Therapeutics（US）、Amicus Therapeutics, Inc（US）、Sanofi（France）、CENTOGENE AG（UK）などの情報が含まれています。
・エグゼクティブサマリー
・イントロダクション
・調査手法
・市場動向
・市場要因分析
・世界のポンペ病治療市場規模：種類別
- 遅発性ポンペ病の市場規模
- 従来型乳児ポンペ病の市場規模
- 非従来型乳児ポンペ病の市場規模
・世界のポンペ病治療市場規模：治療別
- 酵素補充療法（ERT）の市場規模
- 遺伝子治療の市場規模
- その他治療の市場規模
・世界のポンペ病治療市場規模：エンドユーザー別
- 病院・診療所における市場規模
- 研究・学術機関における市場規模
・世界のポンペ病治療市場規模：地域別
- 南北アメリカのポンペ病治療市場規模
- ヨーロッパのポンペ病治療市場規模
- アジア太平洋のポンペ病治療市場規模
- 中東・アフリカのポンペ病治療市場規模
・競争状況
・企業情報

ポンペ病治療の2030年までの市場予測

市場概要：
ポンペ病治療薬の世界市場は、2022～2030年の予測期間中に大きく拡大する見込みです。ポンペ病は、脳細胞の変性を引き起こし、振戦、痙攣、認知機能障害などを引き起こす希少かつ致死的な疾患です。ポンペ病の治療市場は近年拡大しており、アメリカにおける有病率は約200,000人に1人、年間発症率は約800,000万人に1人です。ポンペ病治療市場には、幹細胞移植、骨髄移植、化学療法、免疫療法などの直接消費者に提供される選択肢と、学術医療センターや個人開業医などの医療提供者の両方が含まれます。
ポンペ病治療市場は、ポンペ病の有病率の増加や新たな治療選択肢の登場により、今後数年間で成長すると予想されています。ポンペ病に対する意識の高まりや、酵素補充療法（ERT）のような新しい治療法の利用可能性も、市場成長の原動力になると予想されます。

ERTはポンペ病の治療法として最も一般的に用いられており、標準治療と考えられています。しかし、遺伝子治療や基質還元療法（SRT）など、他の治療法もあります。これらの治療法はまだ開発の初期段階にありますが、臨床試験で有望な結果を示しています。
ポンペ病治療は、新しい治療法の臨床試験数の増加から恩恵を受けると予想されます。将来的には、より効果的な治療法の開発につながることが期待されます。
全体として、ポンペ病治療市場は、ポンペ病の有病率の増加、新たな治療オプションの利用可能性、およびポンペ病に対する意識の高まりにより、今後数年間で成長する見込みです。
また、ポンペ病と診断される患者数の増加や、新規治療法の臨床試験件数の増加も市場を牽引しています。将来的には、より効果的な治療法の開発につながると期待されています。

セグメント概要：
世界のポンペ病治療市場は、タイプ別、治療タイプ別、エンドユーザー別、地域別にセグメント化されています。市場はポンペ病のタイプに基づいて、非定型小児発症ポンペ病、遅発性ポンペ病、定型小児発症ポンペ病の3つの主要カテゴリーに区分されています。治療タイプは、遺伝子治療、酵素補充療法、その他に分けられ、研究・学術機関、病院、クリニックに分類されます。

地域分析：
北米は、先進的な医療インフラが存在し、ポンペ病の有病率が高いことから、市場を支配し、大きなシェアを占めると予想されます。また、償還政策の利用可能性、ポンペ病に関する認知度の向上、同地域における主要市場プレイヤーの存在も、北米の市場成長に寄与しています。
ヨーロッパでは、イタリア、ドイツ、フランスなどの国々が、ポンペ病の有病率の増加と高度な医療インフラの利用可能性により、大きな進展を示すと予想されています。

主要企業：
この市場調査における主要企業には、Oxyrane (UK), Valerion Therapeutics (US), AVROBIO, Inc. (US), Audentes Therapeutics (US), Amicus Therapeutics, Inc (US), Sanofi (France), CENTOGENE AG (UK)などが含まれます。

新型コロナウイルスの影響：
新型コロナウイルスによるパンデミックは、サプライチェーンやポンペ病治療薬の生産に影響を及ぼしています。職場や工場での人手不足により、市場は混乱に直面する可能性があります。しかし、明るい兆しもあります。他の市場と同じように、人間の労働力の代わりに高度な技術が使われています。時折、人間の介入は必要かもしれませんが、それは確かに不足しています。各国政府はワクチン接種を推進しています。新型コロナウイルスパンデミックの最初の数ヶ月は、市場の生産が減少しました。しかし、ポンペ病治療市場は生産のペースを上げています。

グローバル市場調査レポート販売サイトのwww.marketreport.jpです。

❖ レポートの目次 ❖

TABLE OF CONTENT
1 EXECUTIVE SUMMARY
2 MARKET INTRODUCTION
2.1 SCOPE OF THE STUDY 13
2.2 RESEARCH OBJECTIVE 13
2.3 MARKET STRUCTURE 13
2.4 ASSUMPTIONS & LIMITATIONS 14
3 RESEARCH METHODOLOGY
3.1 DATA MINING 15
3.2 SECONDARY RESEARCH 16
3.3 PRIMARY RESEARCH 17
3.4 BREAKDOWN OF PRIMARY RESPONDENTS 18
3.5 FORECASTING TECHNIQUES 19
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 20
3.6.1 BOTTOM-UP APPROACH 20
3.6.2 TOP-DOWN APPROACH 21
3.7 DATA TRIANGULATION 21
3.8 VALIDATION 21
4 MARKET DYNAMICS
4.1 OVERVIEW 22
4.2 DRIVERS 23
4.2.1 INCREASING GOVERNMENT INITIATIVES 23
4.2.2 RISING R&D ACTIVITIES BY MANUFACTURERS 23
4.3 RESTRAINTS 24
4.3.1 HIGH COST OF TREATMENT 24
4.4 OPPORTUNITIES 25
4.4.1 EMERGENCE OF IMMUNOTHERAPEUTIC APPROACHES 25
4.5 CHALLENGES 25
5 MARKET FACTOR ANALYSIS
5.1 VALUE CHAIN ANALYSIS 26
5.1.1 R&D AND DESIGNING 27
5.1.2 MANUFACTURING 27
5.1.3 DISTRIBUTION & SALES 27
5.1.4 POST-SALES SERVICES 27
5.2 PORTER’S FIVE FORCES MODEL 28
5.2.1 BARGAINING POWER OF SUPPLIERS 29
5.2.2 BARGAINING POWER OF BUYERS 29
5.2.3 THREAT OF NEW ENTRANTS 29
5.2.4 THREAT OF SUBSTITUTES 29
5.2.5 INTENSITY OF RIVALRY 29
6 POMPE DISEASE TREATMENT MARKET, BY TYPE
6.1 OVERVIEW 30
6.2 LATE-ONSET POMPE DISEASE 31
6.3 CLASSIC INFANTILE-ONSET POMPE DISEASE 31
6.4 NON-CLASSIC INFANTILE-ONSET POMPE DISEASE 32
7 POMPE DISEASE TREATMENT MARKET, BY THERAPY
7.1 OVERVIEW 33
7.2 ENZYME REPLACEMENT THERAPY (ERT) 34
7.3 GENE THERAPY 34
7.4 OTHERS 34
8 POMPE DISEASE TREATMENT MARKET, BY END USER
8.1 OVERVIEW 35
8.2 HOSPITALS & CLINICS 36
8.3 RESEARCH & ACADEMIC INSTITUTES 36
9 GLOBAL POMPE DISEASE TREATMENT MARKET, BY REGION
9.1 OVERVIEW 37
9.2 AMERICAS 39
POMPE DISEASE TREATMENT MARKET, BY TYPE
POMPE DISEASE TREATMENT MARKET, BY THERAPY
POMPE DISEASE TREATMENT MARKET, BY END USER
9.2.1 NORTH AMERICA 40
POMPE DISEASE TREATMENT MARKET, BY TYPE
POMPE DISEASE TREATMENT MARKET, BY THERAPY
POMPE DISEASE TREATMENT MARKET, BY END USER
9.2.1.1 US 42
POMPE DISEASE TREATMENT MARKET, BY TYPE
POMPE DISEASE TREATMENT MARKET, BY THERAPY
POMPE DISEASE TREATMENT MARKET, BY END USER
9.2.1.2 CANADA 43
POMPE DISEASE TREATMENT MARKET, BY TYPE
POMPE DISEASE TREATMENT MARKET, BY THERAPY
POMPE DISEASE TREATMENT MARKET, BY END USER
9.2.2 SOUTH AMERICA 44
POMPE DISEASE TREATMENT MARKET, BY TYPE
POMPE DISEASE TREATMENT MARKET, BY THERAPY
POMPE DISEASE TREATMENT MARKET, BY END USER
9.3 EUROPE 46
POMPE DISEASE TREATMENT MARKET, BY TYPE
POMPE DISEASE TREATMENT MARKET, BY THERAPY
POMPE DISEASE TREATMENT MARKET, BY END USER
9.3.1 GERMANY 48
POMPE DISEASE TREATMENT MARKET, BY TYPE
POMPE DISEASE TREATMENT MARKET, BY THERAPY
POMPE DISEASE TREATMENT MARKET, BY END USER
9.3.2 FRANCE 49
POMPE DISEASE TREATMENT MARKET, BY TYPE
POMPE DISEASE TREATMENT MARKET, BY THERAPY
POMPE DISEASE TREATMENT MARKET, BY END USER
9.3.3 UK 50
POMPE DISEASE TREATMENT MARKET, BY TYPE
POMPE DISEASE TREATMENT MARKET, BY THERAPY
POMPE DISEASE TREATMENT MARKET, BY END USER
9.3.4 ITALY 51
POMPE DISEASE TREATMENT MARKET, BY TYPE
POMPE DISEASE TREATMENT MARKET, BY THERAPY
POMPE DISEASE TREATMENT MARKET, BY END USER
9.3.5 SPAIN 52
POMPE DISEASE TREATMENT MARKET, BY TYPE
POMPE DISEASE TREATMENT MARKET, BY THERAPY
POMPE DISEASE TREATMENT MARKET, BY END USER
9.3.6 REST OF EUROPE 53
POMPE DISEASE TREATMENT MARKET, BY TYPE
POMPE DISEASE TREATMENT MARKET, BY THERAPY
POMPE DISEASE TREATMENT MARKET, BY END USER
9.4 ASIA-PACIFIC 54
POMPE DISEASE TREATMENT MARKET, BY TYPE
POMPE DISEASE TREATMENT MARKET, BY THERAPY
POMPE DISEASE TREATMENT MARKET, BY END USER
9.4.1 CHINA 56
POMPE DISEASE TREATMENT MARKET, BY TYPE
POMPE DISEASE TREATMENT MARKET, BY THERAPY
POMPE DISEASE TREATMENT MARKET, BY END USER
9.4.2 JAPAN 57
POMPE DISEASE TREATMENT MARKET, BY TYPE
POMPE DISEASE TREATMENT MARKET, BY THERAPY
POMPE DISEASE TREATMENT MARKET, BY END USER
9.4.3 INDIA 58
POMPE DISEASE TREATMENT MARKET, BY TYPE
POMPE DISEASE TREATMENT MARKET, BY THERAPY
POMPE DISEASE TREATMENT MARKET, BY END USER
9.4.4 SOUTH KOREA 59
POMPE DISEASE TREATMENT MARKET, BY TYPE
POMPE DISEASE TREATMENT MARKET, BY THERAPY
POMPE DISEASE TREATMENT MARKET, BY END USER
9.4.5 AUSTRALIA 60
POMPE DISEASE TREATMENT MARKET, BY TYPE
POMPE DISEASE TREATMENT MARKET, BY THERAPY
POMPE DISEASE TREATMENT MARKET, BY END USER
9.4.6 REST OF ASIA-PACIFIC 61
POMPE DISEASE TREATMENT MARKET, BY TYPE
POMPE DISEASE TREATMENT MARKET, BY THERAPY
POMPE DISEASE TREATMENT MARKET, BY END USER
9.5 MIDDLE EAST & AFRICA 62
POMPE DISEASE TREATMENT MARKET, BY TYPE
POMPE DISEASE TREATMENT MARKET, BY THERAPY
POMPE DISEASE TREATMENT MARKET, BY END USER
9.5.1 MIDDLE EAST 63
POMPE DISEASE TREATMENT MARKET, BY TYPE
POMPE DISEASE TREATMENT MARKET, BY THERAPY
POMPE DISEASE TREATMENT MARKET, BY END USER
9.5.2 AFRICA 64
POMPE DISEASE TREATMENT MARKET, BY TYPE
POMPE DISEASE TREATMENT MARKET, BY THERAPY
POMPE DISEASE TREATMENT MARKET, BY END USER
10 COMPETITIVE LANDSCAPE
10.1 OVERVIEW 66
10.2 MAJOR PLAYERS IN THE GLOBAL POMPE DISEASE TREATMENT MARKET 66
10.3 COMPETITIVE BENCHMARKING 67
10.4 COMPETITOR DASHBOARD 68
10.5 MAJOR GROWTH STRATEGY IN THE GLOBAL POMPE DISEASE TREATMENT MARKET 69
10.6 THE LEADING PLAYER IN TERMS OF NUMBER OF DEVELOPMENTS IN GLOBAL POMPE DISEASE TREATMENT
MARKET 69
10.7 KEY DEVELOPMENTS & GROWTH STRATEGIES 70
10.7.1 EXPANSION 70
10.7.2 ANNOUNCEMENT 71
10.7.3 PATENT 71
10.7.4 DEVELOPMENTS 71
10.7.5 DEFINITIVE AGREEMENT 71
11 COMPANY PROFILES
11.1 AMICUS THERAPEUTICS, INC 72
11.1.1 COMPANY OVERVIEW 72
11.1.2 FINANCIAL OVERVIEW 72
11.1.3 PRODUCTS/SERVICES OFFERED 72
11.1.4 KEY DEVELOPMENTS 73
11.1.5 SWOT ANALYSIS 73
11.1.6 KEY STRATEGIES 73
11.2 SANOFI 74
11.2.1 COMPANY OVERVIEW 74
11.2.2 FINANCIAL OVERVIEW 74
11.2.3 PRODUCTS/SERVICES OFFERED 75
11.2.4 KEY DEVELOPMENTS 75
11.2.5 SWOT ANALYSIS 76
11.2.6 KEY STRATEGIES 76
11.3 AUDENTES THERAPEUTICS 77
11.3.1 COMPANY OVERVIEW 77
11.3.2 FINANCIAL OVERVIEW 77
11.3.3 PRODUCTS/SERVICES OFFERED 77
11.3.4 KEY DEVELOPMENTS 78
11.3.5 SWOT ANALYSIS 78
11.3.6 KEY STRATEGIES 78
11.4 OXYRANE 79
11.4.1 COMPANY OVERVIEW 79
11.4.2 FINANCIAL OVERVIEW 79
11.4.3 PRODUCTS/SERVICES OFFERED 79
11.4.4 KEY DEVELOPMENTS 79
11.4.5 SWOT ANALYSIS 80
11.4.6 KEY STRATEGIES 80
11.5 VALERION THERAPEUTICS 81
11.5.1 COMPANY OVERVIEW 81
11.5.2 FINANCIAL OVERVIEW 81
11.5.3 PRODUCTS/SERVICES OFFERED 81
11.5.4 KEY DEVELOPMENTS 81
11.5.5 SWOT ANALYSIS 82
11.5.6 KEY STRATEGIES 82
11.6 AVROBIO, INC. 83
11.6.1 COMPANY OVERVIEW 83
11.6.2 FINANCIAL OVERVIEW 83
11.6.3 PRODUCTS/SERVICES OFFERED 84
11.6.4 KEY DEVELOPMENTS 84
11.6.5 SWOT ANALYSIS 84
11.6.6 KEY STRATEGIES 84
11.7 CENTOGENE AG 85
11.7.1 COMPANY OVERVIEW 85
11.7.2 FINANCIAL OVERVIEW 85
11.7.3 PRODUCTS/SERVICES OFFERED 85
11.7.4 KEY DEVELOPMENTS 85
11.7.5 SWOT ANALYSIS 86
11.7.6 KEY STRATEGIES 86
12 APPENDIX
12.1 REFERENCES 87
12.2 RELATED REPORTS 87

LIST OF TABLES
TABLE 1 LIST OF ASSUMPTIONS 14
TABLE 2 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS 17
TABLE 3 GLOBAL POMPE DISEASE TREATMENT MARKET, BY TYPE 2016–2030 (USD MILLION) 30
TABLE 4 GLOBAL POMPE DISEASE TREATMENT MARKET, FOR LATE-ONSET POMPE DISEASE, BY REGION 2016–2030 (USD MILLION) 31
TABLE 5 GLOBAL POMPE DISEASE TREATMENT MARKET, FOR CLASSIC INFANTILE-ONSET POMPE DISEASE, BY REGION 2016–2030
(USD MILLION) 31
TABLE 6 GLOBAL POMPE DISEASE TREATMENT MARKET, FOR NON-CLASSIC INFANTILE-ONSET POMPE DISEASE, BY REGION 2016–2030
(USD MILLION) 32
TABLE 7 GLOBAL POMPE DISEASE TREATMENT MARKET, BY THERAPY 2016–2030 (USD MILLION) 33
TABLE 8 GLOBAL POMPE DISEASE TREATMENT MARKET, FOR ENZYME REPLACEMENT THERAPY (ERT), BY REGION 2016–2030
(USD MILLION) 34
TABLE 9 GLOBAL POMPE DISEASE TREATMENT MARKET, FOR GENE THERAPY, BY REGION 2016–2030 (USD MILLION) 34
TABLE 10 GLOBAL POMPE DISEASE TREATMENT MARKET, BY END USER 2016–2030 (USD MILLION) 35
TABLE 11 GLOBAL POMPE DISEASE TREATMENT MARKET, FOR HOSPITALS & CLINICS, BY REGION 2016–2030 (USD MILLION) 36
TABLE 12 GLOBAL POMPE DISEASE TREATMENT MARKET, FOR RESEARCH & ACADEMIC INSTITUTES, BY REGION 2016–2030
(USD MILLION) 36
TABLE 13 GLOBAL POMPE DISEASE TREATMENT MARKET, BY REGION 2016–2030 (USD MILLION) 37
TABLE 14 AMERICAS: POMPE DISEASE TREATMENT MARKET, BY REGION 2016–2030 (USD MILLION) 39
TABLE 15 AMERICAS: POMPE DISEASE TREATMENT MARKET, BY TYPE 2016–2030 (USD MILLION) 39
TABLE 16 AMERICAS: POMPE DISEASE TREATMENT MARKET, BY THERAPY 2016–2030 (USD MILLION) 40
TABLE 17 AMERICAS: POMPE DISEASE TREATMENT MARKET, BY END USER 2016–2030 (USD MILLION) 40
TABLE 18 NORTH AMERICA: POMPE DISEASE TREATMENT MARKET, BY COUNTRY 2016–2030 (USD MILLION) 40
TABLE 19 NORTH AMERICA: POMPE DISEASE TREATMENT MARKET, BY TYPE 2016–2030 (USD MILLION) 41
TABLE 20 NORTH AMERICA: POMPE DISEASE TREATMENT MARKET, BY THERAPY 2016–2030 (USD MILLION) 41
TABLE 21 NORTH AMERICA: POMPE DISEASE TREATMENT MARKET, BY END USER 2016–2030 (USD MILLION) 42
TABLE 22 US: POMPE DISEASE TREATMENT MARKET, BY TYPE 2016–2030 (USD MILLION) 42
TABLE 23 US: POMPE DISEASE TREATMENT MARKET, BY THERAPY 2016–2030 (USD MILLION) 42
TABLE 24 US: POMPE DISEASE TREATMENT MARKET, BY END USER 2016–2030 (USD MILLION) 43
TABLE 25 CANADA: POMPE DISEASE TREATMENT MARKET, BY TYPE 2016–2030 (USD MILLION) 43
TABLE 26 CANADA: POMPE DISEASE TREATMENT MARKET, BY THERAPY 2016–2030 (USD MILLION) 43
TABLE 27 CANADA: POMPE DISEASE TREATMENT MARKET, BY END USER 2016–2030 (USD MILLION) 44
TABLE 28 SOUTH AMERICA: POMPE DISEASE TREATMENT MARKET, BY TYPE 2016–2030 (USD MILLION) 44
TABLE 29 SOUTH AMERICA: POMPE DISEASE TREATMENT MARKET, BY THERAPY 2016–2030 (USD MILLION) 44
TABLE 30 SOUTH AMERICA: POMPE DISEASE TREATMENT MARKET, BY END USER 2016–2030 (USD MILLION) 45
TABLE 31 EUROPE: POMPE DISEASE TREATMENT MARKET, BY COUNTRY 2016–2030 (USD MILLION) 46
TABLE 32 EUROPE: POMPE DISEASE TREATMENT MARKET, BY TYPE 2016–2030 (USD MILLION) 47
TABLE 33 EUROPE: POMPE DISEASE TREATMENT MARKET, BY THERAPY 2016–2030 (USD MILLION) 47
TABLE 34 EUROPE: POMPE DISEASE TREATMENT MARKET, BY END USER 2016–2030 (USD MILLION) 47
TABLE 35 GERMANY: POMPE DISEASE TREATMENT MARKET, BY TYPE 2016–2030 (USD MILLION) 48
TABLE 36 GERMANY: POMPE DISEASE TREATMENT MARKET, BY THERAPY 2016–2030 (USD MILLION) 48
TABLE 37 GERMANY: POMPE DISEASE TREATMENT MARKET, BY END USER 2016–2030 (USD MILLION) 48
TABLE 38 FRANCE: POMPE DISEASE TREATMENT MARKET, BY TYPE 2016–2030 (USD MILLION) 49
TABLE 39 FRANCE: POMPE DISEASE TREATMENT MARKET, BY THERAPY 2016–2030 (USD MILLION) 49
TABLE 40 FRANCE: POMPE DISEASE TREATMENT MARKET, BY END USER 2016–2030 (USD MILLION) 49
TABLE 41 UK: POMPE DISEASE TREATMENT MARKET, BY TYPE 2016–2030 (USD MILLION) 50
TABLE 42 UK: POMPE DISEASE TREATMENT MARKET, BY THERAPY 2016–2030 (USD MILLION) 50
TABLE 43 UK: POMPE DISEASE TREATMENT MARKET, BY END USER 2016–2030 (USD MILLION) 50
TABLE 44 ITALY: POMPE DISEASE TREATMENT MARKET, BY TYPE 2016–2030 (USD MILLION) 51
TABLE 45 ITALY: POMPE DISEASE TREATMENT MARKET, BY THERAPY 2016–2030 (USD MILLION) 51
TABLE 46 ITALY: POMPE DISEASE TREATMENT MARKET, BY END USER 2016–2030 (USD MILLION) 51
TABLE 47 SPAIN: POMPE DISEASE TREATMENT MARKET, BY TYPE 2016–2030 (USD MILLION) 52
TABLE 48 SPAIN: POMPE DISEASE TREATMENT MARKET, BY THERAPY 2016–2030 (USD MILLION) 52
TABLE 49 SPAIN: POMPE DISEASE TREATMENT MARKET, BY END USER 2016–2030 (USD MILLION) 52
TABLE 50 REST OF EUROPE: POMPE DISEASE TREATMENT MARKET, BY TYPE 2016–2030 (USD MILLION) 53
TABLE 51 REST OF EUROPE: POMPE DISEASE TREATMENT MARKET, BY THERAPY 2016–2030 (USD MILLION) 53
TABLE 52 REST OF EUROPE: POMPE DISEASE TREATMENT MARKET, BY END USER 2016–2030 (USD MILLION) 53
TABLE 53 ASIA-PACIFIC: POMPE DISEASE TREATMENT MARKET, BY COUNTRY 2016–2030 (USD MILLION) 54
TABLE 54 ASIA-PACIFIC: POMPE DISEASE TREATMENT MARKET, BY TYPE 2016–2030 (USD MILLION) 55
TABLE 55 ASIA-PACIFIC: POMPE DISEASE TREATMENT MARKET, BY THERAPY 2016–2030 (USD MILLION) 55
TABLE 56 ASIA-PACIFIC: POMPE DISEASE TREATMENT MARKET, BY END USER 2016–2030 (USD MILLION) 55
TABLE 57 CHINA: POMPE DISEASE TREATMENT MARKET, BY TYPE 2016–2030 (USD MILLION) 56
TABLE 58 CHINA: POMPE DISEASE TREATMENT MARKET, BY THERAPY 2016–2030 (USD MILLION) 56
TABLE 59 CHINA: POMPE DISEASE TREATMENT MARKET, BY END USER 2016–2030 (USD MILLION) 56
TABLE 60 JAPAN: POMPE DISEASE TREATMENT MARKET, BY TYPE 2016–2030 (USD MILLION) 57
TABLE 61 JAPAN: POMPE DISEASE TREATMENT MARKET, BY THERAPY 2016–2030 (USD MILLION) 57
TABLE 62 JAPAN: POMPE DISEASE TREATMENT MARKET, BY END USER 2016–2030 (USD MILLION) 57
TABLE 63 INDIA: POMPE DISEASE TREATMENT MARKET, BY TYPE 2016–2030 (USD MILLION) 58
TABLE 64 INDIA: POMPE DISEASE TREATMENT MARKET, BY THERAPY 2016–2030 (USD MILLION) 58
TABLE 65 INDIA: POMPE DISEASE TREATMENT MARKET, BY END USER 2016–2030 (USD MILLION) 58
TABLE 66 SOUTH KOREA: POMPE DISEASE TREATMENT MARKET, BY TYPE 2016–2030 (USD MILLION) 59
TABLE 67 SOUTH KOREA: POMPE DISEASE TREATMENT MARKET, BY THERAPY 2016–2030 (USD MILLION) 59
TABLE 68 SOUTH KOREA: POMPE DISEASE TREATMENT MARKET, BY END USER 2016–2030 (USD MILLION) 59
TABLE 69 AUSTRALIA: POMPE DISEASE TREATMENT MARKET, BY TYPE 2016–2030 (USD MILLION) 60
TABLE 70 AUSTRALIA: POMPE DISEASE TREATMENT MARKET, BY THERAPY 2016–2030 (USD MILLION) 60
TABLE 71 AUSTRALIA: POMPE DISEASE TREATMENT MARKET, BY END USER 2016–2030 (USD MILLION) 60
TABLE 72 REST OF ASIA-PACIFIC: POMPE DISEASE TREATMENT MARKET, BY TYPE 2016–2030 (USD MILLION) 61
TABLE 73 REST OF ASIA-PACIFIC: POMPE DISEASE TREATMENT MARKET, BY THERAPY 2016–2030 (USD MILLION) 61
TABLE 74 REST OF ASIA-PACIFIC: POMPE DISEASE TREATMENT MARKET, BY END USER 2016–2030 (USD MILLION) 61
TABLE 75 MIDDLE EAST & AFRICA: POMPE DISEASE TREATMENT MARKET, BY REGION 2016–2030 (USD MILLION) 62
TABLE 76 MIDDLE EAST & AFRICA: POMPE DISEASE TREATMENT MARKET, BY TYPE 2016–2030 (USD MILLION) 62
TABLE 77 MIDDLE EAST & AFRICA: POMPE DISEASE TREATMENT MARKET, BY THERAPY 2016–2030 (USD MILLION) 63
TABLE 78 MIDDLE EAST & AFRICA: POMPE DISEASE TREATMENT MARKET, BY END USER 2016–2030 (USD MILLION) 63
TABLE 79 MIDDLE EAST: POMPE DISEASE TREATMENT MARKET, BY TYPE 2016–2030 (USD MILLION) 63
TABLE 80 MIDDLE EAST: POMPE DISEASE TREATMENT MARKET, BY THERAPY 2016–2030 (USD MILLION) 64
TABLE 81 MIDDLE EAST: POMPE DISEASE TREATMENT MARKET, BY END USER 2016–2030 (USD MILLION) 64
TABLE 82 AFRICA: POMPE DISEASE TREATMENT MARKET, BY TYPE 2016–2030 (USD MILLION) 64
TABLE 83 AFRICA: POMPE DISEASE TREATMENT MARKET, BY THERAPY 2016–2030 (USD MILLION) 65
TABLE 84 AFRICA: POMPE DISEASE TREATMENT MARKET, BY END USER 2016–2030 (USD MILLION) 65
TABLE 85 MAJOR PLAYERS IN THE GLOBAL POMPE DISEASE TREATMENT MARKET 66
TABLE 86 COMPETITOR DASHBOARD: GLOBAL POMPE DISEASE TREATMENT MARKET 68
TABLE 87 THE MOST ACTIVE PLAYER IN THE GLOBAL POMPE DISEASE TREATMENT MARKET 69
TABLE 88 EXPANSION 70
TABLE 89 ANNOUNCEMENT 71
TABLE 90 PATENT 71
TABLE 91 DEVELOPMENTS 71
TABLE 92 DEFINITIVE AGREEMENT 71
TABLE 93 AMICUS THERAPEUTICS, INC: FINANCIAL INFORMATION 72
TABLE 94 AMICUS THERAPEUTICS, INC: PRODUCTS/SERVICES OFFERED 72
TABLE 95 AMICUS THERAPEUTICS, INC: KEY DEVELOPMENTS 73
TABLE 96 SANOFI: FINANCIAL INFORMATION 74
TABLE 97 SANOFI : PRODUCTS/SERVICES OFFERED 75
TABLE 98 SANOFI : KEY DEVELOPMENTS 75
TABLE 99 AUDENTES THERAPEUTICS: FINANCIAL INFORMATION 77
TABLE 100 AUDENTES THERAPEUTICS : PRODUCTS/SERVICES OFFERED 77
TABLE 101 AUDENTES THERAPEUTICS: KEY DEVELOPMENTS 78
TABLE 102 OXYRANE : PRODUCTS/SERVICES OFFERED 79
TABLE 103 VALERION THERAPEUTICS : PRODUCTS/SERVICES OFFERED 81
TABLE 104 VALERION THERAPEUTICS: KEY DEVELOPMENTS 81
TABLE 105 AVROBIO, INC.: FINANCIAL INFORMATION 83
TABLE 106 AVROBIO, INC.: PRODUCTS/SERVICES OFFERED 84
TABLE 107 CENTOGENE AG : PRODUCTS/SERVICES OFFERED 85
TABLE 108 CENTOGENE AG : KEY DEVELOPMENTS 85

★調査レポート[世界のポンペ病治療市場（〜2030年）] (コード：MRF23JUN012)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界のポンペ病治療市場（〜2030年）]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 世界のダーカム病市場（〜2030年）
  • 血栓治療の世界市場予測（～2030年）
  • 世界の尋常性白斑治療市場（〜2030年）
  • 世界の羊膜市場（〜2030年）
  • 世界のムコ多糖症治療市場（2023年-2030年）
  • 世界の骨生検市場（〜2030年）
  • 世界のプレフィルドシリンジ市場（〜2030年）

    • ◆H&Iグローバルリサーチのお客様（例）◆